Amyloid PET shows good additive value when standard PET isn’t conclusive on dementia

Patients with suspected dementia that remains unclarified after PET imaging with the standard radiotracer fluordeoxyglucose (FDG) should be sent for amyloid-busting PET with florbetaben (FBB), as the latter is highly useful in establishing a final diagnosis in such situations.

Matthias Brendel, MD, of Ludwig-Maximilian University Hospital in Munich and colleagues published the findings behind the conclusion online Sept. 20 in the European Journal of Nuclear Medicine and Molecular Imaging.

The researchers looked at the cases of all patients who underwent FDG-PET at their institution after presenting with symptoms of neurodegenerative disease.

An interdisciplinary dementia board determined that 107 patients (mean age 69.4 ± 9.7 years) had persistently uncertain diagnoses and so should be sent for additional imaging with FBB-PET.

After classifying the results as amyloid-positive (65 of the 107) or amyloid-negative, the team compared the individual clinical diagnoses before and after the FBB-PET.

They found that a final diagnosis was reached through FBB-PET in 83 percent of the formerly unclear cases, and the most likely prior diagnosis was changed in 28 percent of cases.

Meanwhile, the highest impact was observed for distinguishing Alzheimer’s dementia from frontotemporal dementia.

Here the FBB-PET altered the most likely diagnosis in some 41 percent of cases.

“FBB-PET has a high additive value in establishing a final diagnosis in suspected dementia cases when prior investigations such as FDG-PET are inconclusive,” Brendel et al. conclude. “The differentiation between Alzheimer’s disease and frontotemporal dementia was particularly facilitated by amyloid-PET, predicting a considerable impact on patient management, especially in the light of upcoming disease-modifying therapies.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

Trimed Popup
Trimed Popup